Skip to main content
. Author manuscript; available in PMC: 2016 May 15.
Published in final edited form as: Clin Cancer Res. 2015 May 15;21(10):2221–2226. doi: 10.1158/1078-0432.CCR-14-3154

Table 1.

Representative EGFR TKIs currently in use or development

First generation (target WT EGFR) Second generation (irreversible inhibitors of EGFR and HER2) Third generation (EGFR mutant-specific, irreversible inhibitors)

Erlotinib* Neratinib Rociletinib (Clovis)
Gefitinib Afatinib* AZD9291 (AstraZeneca)
Icotinib Dacomitinib HM61713 (Hanmi)
EGF816 (Novartis)
ASP8273 (Astellas)
*

FDA-approved in the US for treatment of lung cancer

HHS Vulnerability Disclosure